Objective: To evaluate the therapeutic dose and safety of bemiparin in neonatal thrombosis treatment.
Study Design: A retrospective review was conducted on infants treated with bemiparin between 2018 and 2023 at a tertiary hospital.
Results: 72 neonates with a mean gestational age of 37 weeks were included.